Antimicrobial susceptibility and combination testing of invasive Stenotrophomonas maltophilia isolates

Scandinavian Journal of Infectious Diseases

Volumn 45, Issue 4, 2013, Pages 265-270

  Church, Deirdre ^a,b   Lloyd, Tracie ^a   Peirano, Gisele ^a   Pitout, Johann ^a,b  

^a CALGARY LABORATORY SERVICES   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Antimicrobial susceptibility; Combination testing; Invasive Stenotrophomonas maltophilia

Indexed keywords

CEFTAZIDIME; COLISTIN; LEVOFLOXACIN; MINOCYCLINE; TIGECYCLINE; TIMENTIN;

ADULT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; BLOOD ANALYSIS; BROTH DILUTION; CEREBROSPINAL FLUID; CHILD; DRUG POTENTIATION; EPSILOMETER TEST; FEMALE; GENOTYPE; HUMAN; IN VITRO STUDY; INFANT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRESCHOOL CHILD; RESPIRATORY SYSTEM; SCHOOL CHILD; STENOTROPHOMONAS MALTOPHILIA;

ADULT; ANTI-BACTERIAL AGENTS; CHILD; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; GENOTYPE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFANT; MICROBIAL SENSITIVITY TESTS; MOLECULAR TYPING; POLYMERASE CHAIN REACTION; STENOTROPHOMONAS MALTOPHILIA; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84875448091     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2012.732240     Document Type: Article

References (26)

1. Aisenberg,G,R olston KV, Dickey BF, Kontoyiannis DP, Raad, II, Safdar A. Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997-2004. Eur J Clin Microbiol Infect Dis 2007; 26 : 13-20.
2. Ansari SR, Hanna H, Hachem R, Jiang Y, Rolston K, Raad I. Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer. Cancer 2007 ; 109 : 2615-22.
3. Crum N F, Utz GC, Wallace MR. S tenotrophomonas maltophilia endocarditis. Scand J Infect Dis 2002 ; 34 : 925-7.
4. Hanes SD, Demirkan K, Tolley E, Boucher BA, Croce MA, Wood GC, et al. Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis 2002 ; 35 : 228-35.
5. Lai CH, Chi CY, Chen HP, Chen TL, Lai CJ, Fung CP, et al. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J Microbiol Immunol Infect 2004 ; 37 : 350-8.
6. L eroy O, d 'E scrivan T, Devos P, Dubreuil L, Kipnis E, Georges H. Hospital-acquired pneumonia in critically ill patients: factors associated with episodes due to imipenemresistant organisms. Infection 2005 ; 33 : 129-35.
7. Tsai W P, Chen C L, Ko W C, Pan S C. S tenotrophomonas maltophilia bacteremia in burn patients. Burns 2006 ; 32 : 155-8.
8. Tzanetou K, Triantaphillis G, Tsoutsos D, Petropoulou D, Ganteris G, Malamou-Lada E, et al. Stenotrophomonas maltophilia peritonitis in CAPD patients: susceptibility to antibiotics and treatment outcome: a report of fi ve cases. Perit Dial Int 2004 ; 24 : 401-4.
9. Yeshurun M, Gafter-Gvili A, Thaler M, Keller N, Nagler A, Shimoni A. Clinical characteristics of Stenotrophomonas maltophilia infection in hematopoietic stem cell transplantation recipients: a single center experience. Infection 2010 ; 38 : 211-5.
10. Senol E, DesJardin J, Stark PC, Barefoot L, Snydman DR. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis 2002 ; 34 : 1653-6.
11. N seir S, Di Pompeo C, Brisson H, Dewavrin F, Tissier S, Diarra M, et al. Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome. Crit Care 2006 ; 10 : R143.
12. Gales AC, Jones R N, Forward K R, Linares J, Sader H S, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999 ). Clin Infect Dis 2001 ; 32(Suppl 2) : S104-13.
13. Zhang L, Li X Z, Poole K. S meDEF multidrug effl ux pump contributes to intrinsic multidrug resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2001 ; 45 : 3497-503.
14. Mercuri P S, Ishii Y, Ma L, Rossolini G M, Luzzaro F, Amicosante G, et al. Clonal diversity and metallo-betalactamase production in clinical isolates of Stenotrophomonas maltophilia. Microb Drug Resist 2002l ; 8 : 193-200.
15. Nicodemo AC, Paez JI. A ntimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis 2007 ; 26 : 229-37.
16. Al-Jasser A M. S tenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem. Ann Clin Microbiol Antimicrob 2006 ; 5 : 23.
17. Barbolla R, Catalano M, Orman BE, Famiglietti A, Vay C, Smayevsky J, et al. Class 1 integrons increase trimethoprim-sulfamethoxazole MICs against epidemiologically unrelated Stenotrophomonas maltophilia isolates. Antimicrob Agents Chemother 2004 ; 48 : 666-9.
18. Farrell DJ, Sader HS, Jones RN. A ntimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother 2010 ; 54 : 2735-7.
19. Gulmez D, Cakar A, Sener B, Karakaya J, Hascelik G. Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing. J Infect Chemother 2010 ; 16 : 322-8.
20. V isalli MA, Jacobs MR, Appelbaum PC. A ctivities of three quinolones, alone and in combination with extended-spectrum cephalosporins or gentamicin, against Stenotrophomonas maltophilia. Antimicrob Agents Chemother 1998 ; 42 : 2002-5.
21. White R L, Burgess D S, Manduru M, Bosso J A. C omparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother 1996 ; 40 : 1914-8. Zelenitsky
22. Zelenitsky S A, Iacovides H, Ariano R E, Harding G K. Antibiotic combinations signifi cantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 2005 ; 51 : 39-43.
23. Greer ND. T igecycline (Tygacil): the fi rst in the glycylcycline class of antibiotics. Proc (Bayl Univ Med Cent) 2006 ; 19 : 155-61.
24. Clinical and Laboratory Standards Institute. P erformance standards for antimicrobial susceptibility testing: twenty second informational supplement. M100-S22. Wayne, PA: CLSI ; 2012.
25. Gales A C, Jones RN, Andrade SS, Pereira A S, Sader HS. In vitro activity of tigecycline, anew glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America. Braz J Infect Dis 2005 ; 9 : 348-56.
26. Tsiodras S, Pittet D, Carmeli Y, Eliopoulos G, Boucher H, Harbarth S. Clinical implications of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals. Scand J Infect Dis 2000 ; 32 : 651-6.